Luke Meininger

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “The immunocytokine M9241 in the treatment of prostate cancer (PCa): Clinical and immune data from a phase 1 study.”.

The immunocytokine M9241 in the treatment of prostate cancer (PCa): Clinical and immune data from a phase 1 study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.127

N/A

0DataRank · unranked

4 citations

Ravi A. Madan, Nicole J. Toney, Renee N. Donahue, Margaret E. Gatti‐Mays, Julius Strauss +12 more

Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.093

N/A

0DataRank · unranked

4 citations

Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilušić, Jennifer L. Marté +15 more

Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17033

N/A

0DataRank · unranked

3 citations

Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilušić, Jennifer L. Marté +15 more